BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1438437)

  • 21. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graft versus host disease prophylaxis today.
    Martelli MF; Aversa F
    Bone Marrow Transplant; 1991; 7 Suppl 2():112-6. PubMed ID: 1908726
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Minnesota antilymphocyte globulin on T-lymphocytes and their subsets during induction therapy in pediatric renal transplantation.
    Troppmann C; Almond PS; Fasola C; Benedetti E; Gruessner RW; Dunn DL; Gores PF; Payne WD; Matas AJ; Najarian JS
    Transplant Proc; 1994 Feb; 26(1):26-7. PubMed ID: 8108968
    [No Abstract]   [Full Text] [Related]  

  • 25. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
    Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
    Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
    [No Abstract]   [Full Text] [Related]  

  • 26. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
    Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laboratory control in predicting clinical efficacy of T cell-depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis.
    Marciniak E; Romond EH; Thompson JS; Henslee PJ
    Bone Marrow Transplant; 1988 Nov; 3(6):589-98. PubMed ID: 3063328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
    Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2614-5. PubMed ID: 3274569
    [No Abstract]   [Full Text] [Related]  

  • 31. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical use of elutriation and positive stem cell selection columns to engineer the lymphocyte and stem cell composition of the allograft.
    Noga SJ; Davis J; Schepers K; Eby L; Berenson RJ
    Prog Clin Biol Res; 1994; 389():317-24. PubMed ID: 7535437
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation.
    Kawanishi Y; Passweg J; Drobyski WR; Rowlings P; Cook-Craig A; Casper J; Pietryga D; Garbrecht F; Camitta B; Horowitz M; Juckett M; Margolis D; Flomenberg N; Keever-Taylor CA
    Bone Marrow Transplant; 1997 Jun; 19(11):1069-77. PubMed ID: 9193748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro manipulation of bone marrow cells for bone marrow transplantation].
    Morishima Y
    Gan To Kagaku Ryoho; 1988 Nov; 15(11):3034-43. PubMed ID: 3056275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
    J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
    Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
    Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous bone marrow transplantation for acute lymphoblastic leukemia: role of bone marrow purging.
    Canals C; Picón M; Sanchez T; Torrico C; Amill B; Tugues D; Sierra J; Grañena A; Badell I; Brunet S
    Prog Clin Biol Res; 1994; 389():125-32. PubMed ID: 7700894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.